Effectiveness and Tolerability of the α-Glucosidase Inhibitor Acarbose in NIDDM Patients with Elevated Liver Enzyme Activity
Acarbose is a glucosidase inhibitor which exerts its activities within the gastrointestinal tract on brush-border digestion and absorption of sucrose and maltose. Only 1%–2% of the drug is absorbed from the intestine into the systemic circulation. This low systemic availability is, of course, not relevant for the therapeutic effect of the substance, but possibly is relevant for the systemic side effects. Therefore, it is important to investigate the effect of acarbose on the metabolism of patients in whom elevated liver enzymes could be a reference for possible impairments of liver function.